Irbesartan
| Code | Size | Price |
|---|
| CDX-I0204-M050 | 50 mg | £108.00 |
Quantity:
| CDX-I0204-M250 | 250 mg | £401.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
2-Butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one; Avapro; BMS-186295; SR-47436
Appearance:
White to off-white powder.
CAS:
138402-11-6
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
InChiKey:
YOSHYTLCDANDAN-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 138402-11-6. Formula: C25H28N6O. MW: 428.5. Irbesartan is an orally available angiotensin II type 1 (AT1) receptor antagonist (IC50 = 1.3 nM) with antihypertensive activity. It binds to AT1 receptor with >5000 times higher affinity compared to AT2 receptor. Irbesartan also elicits selective peroxisome proliferator-activated receptor gamma (PPARgamma)-modulating activity and exhibits metabolic, anti-inflammatory and antioxidative properties. Irbesartan inhibits the receptor for advanced glycation end-products (RAGE)/high mobility group box 1 (HMGB1) axis and maybe useful in prevention and treatment of various diseases. Formulations containing irbesartan have been used, alone and in combination with diuretics, in the treatment of hypertension.
MDL:
MFCD00864464
Molecular Formula:
C25H28N6O
Molecular Weight:
428.5
Package Type:
Vial
Product Description:
Irbesartan is an orally available angiotensin II type 1 (AT1) receptor antagonist (IC50 = 1.3 nM) with antihypertensive activity. It binds to AT1 receptor with >5000 times higher affinity compared to AT2 receptor. Irbesartan also elicits selective peroxisome proliferator-activated receptor gamma (PPARgamma)-modulating activity and exhibits metabolic, anti-inflammatory and antioxidative properties. Irbesartan inhibits the receptor for advanced glycation end-products (RAGE)/high mobility group box 1 (HMGB1) axis and maybe useful in prevention and treatment of various diseases. Formulations containing irbesartan have been used, alone and in combination with diuretics, in the treatment of hypertension.
Purity:
>98% (HPLC)
SMILES:
O=C1C2(CCCC2)N=C(CCCC)N1CC(C=C3)=CC=C3C4=CC=CC=C4C5=NN=NN5
Solubility Chemicals:
Soluble in DMSO (20mg/ml).
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
References
(1) L. Ruilope; J. Hypertens. Suppl. 15, S15 (1997) (Review) | (2) M. Burnier; Circulation 103, 904 (2001) | (3) A.H. Gradman; J. Human Hypert. 16, S9 (2002) | (4) K. Kikuchi, et al.; Int. J. Mol. Sci. 14, 18899 (2013) (Review) | (5) Z.Z. Zhang, et al.; J. Transl. Med. 11, 229 (2013) | (6) I. Taguchi, et al.; Hypertens. Res. 36, 608 (2013) | (7) I.T. Abdel-Raheem, et al.; Fundam. Clin. Pharmacol. 29, 286 (2015) | (8) J. Zhong, et al.; Int. Immunopharmacol. 42, 176 (2017) | (9) I.A. Darwish, et al.; Prof. Drug Subst. Excip. Rel. Meth. 46, 185 (2021) (Review)